Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program

Event · Exec change
Person
Jørn Skibsted Jakobsen, MD, PhD
Title
Chief Development Officer, Urology & Uro-Oncology
Action
appointed

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 16, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RLMD
Bullish
medium confidence
Mentioned
$RLMD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RLMDBullishLow
01

Why it matters

The appointment signals commitment to advancing NDV-01, potentially reducing execution risk ahead of the Phase 3 SPECTRUM trial.

02

Market read

Exec hire is a modest catalyst for RLMD; limited immediate trading impact but relevant for longer‑term pipeline outlook.

03

What to watch

Execution risk of Phase 3 remains high; leadership change does not guarantee trial success.

Relevance 5/10Novelty 6/10Timing: today

Background

Relmada Therapeutics (NASDAQ:RLMD) is a clinical‑stage biotech developing NDV-01 for non‑muscle invasive bladder cancer and sepranolone for CNS disorders.

Company-level read

Ticker impact

$RLMDBullishMedium confidence
Context

Relmada Therapeutics appointed Jørn Skibsted Jakobsen as Chief Development Officer, Urology & Uro-Oncology, to lead NDV-01 Phase 3 development.

Expected impact

potential slight upside as investors price in stronger development capability

Evidence & confidence

New CDO brings proven uro‑oncology experience; no immediate financial impact but could de‑risk the upcoming Phase 3 trial.

Market effects

May boost sentiment in the biotech uro‑oncology niche, but limited broader sector impact.

U.S. biotech market sees a minor positive cue.

Minimal global effect beyond Relmada.

Counterpoint

Executive hires rarely move small‑cap biotech stocks; the appointment may be priced in already.

Key entities

  • Relmada Therapeutics, Inc.

    Clinical‑stage biotech developing NDV-01 and sepranolone.

  • Jørn Skibsted Jakobsen, MD, PhD

    New Chief Development Officer, Urology & Uro‑Oncology.

Related articles

$RLMDMedAI 8/10

Relmada (RLMD) Q3 2026 Earnings Call Transcript

Relmada (RLMD) reported Q3 2026 progress, including IND submissions for NDV-01 and sepranolone by year-end. NDV-01 showed 86% 18-month CR rate in NMIBC, with favorable safety. Phase 3 trials planned. Cash position of $202.1M expected to fund operations through 2029. Net loss was $13.9M, up from $10.1M YoY.

$RLMDHigh

Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ● NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance ● Long-term extension ND

$RLMDMed

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.

$RLMDMed

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational

$AVGOMed

Google’s 2027 chip plan is bad news for Broadcom

Google plans to reduce its 2027 orders of Broadcom-designed chips by about 1 million units, shifting more to MediaTek. This move, driven by power and supply constraints, has caused Broadcom's stock to fall over 11%. Analysts estimate Broadcom earned $3 billion from Google in 2023, and the reduction could impact its fiscal 2027 revenue growth. Both companies have not yet commented on the report.